search
Back to results

Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality

Primary Purpose

Overweight

Status
Completed
Phase
Not Applicable
Locations
Germany
Study Type
Interventional
Intervention
Standard infant formula
Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin
Sponsored by
Waldkrankenhaus Protestant Hospital, Spandau
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Overweight focused on measuring reduced, protein, formula, Alpha-lactalbumin, infant

Eligibility Criteria

1 Day - 1 Month (Child)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • At the time of study enrollment apparently healthy newborns / infants without pronounced hyper- or hypotrophy (age-appropriate weight percentiles > 3 and < 97 according to Voigt et al.)
  • Maternal decision against breastfeeding (for Formula Groups)

Exclusion Criteria:

  • Congenital gastrointestinal malformations, metabolic disease, chromosomal aberration, syndromic disease with significant impact on growth, development, nutrition, immune competence
  • Manifestation of a serious disease, which is expected to be accompanied by growth retardation, intestinal transit disruption or the need for special dietary treatment (e.g. hypertrophic pyloric stenosis, cystic fibrosis, Hirschsprung's disease, cow's milk protein intolerance.)
  • Decision to administer HA (hypoallergenic) formula due to family atopies (defined by atopic disease of at least one 1 st degree relative: bronchial asthma, atopic dermatitis, pollinosis)
  • Participation in another nutritional study

Sites / Locations

  • Evangelisches Waldkrankenhaus Spandau

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Active Comparator

Experimental

No Intervention

Arm Label

Standard infant formula

Protein reduced formula

Breast-feeding

Arm Description

Standard infant formula

Protein reduced alpha-lactalbumin formula

Exclusive breast-feeding

Outcomes

Primary Outcome Measures

Composite measure of Growth
height, body weight, head circumference

Secondary Outcome Measures

Daily fluid intake
ml/kg/d

Full Information

First Posted
June 9, 2015
Last Updated
June 5, 2020
Sponsor
Waldkrankenhaus Protestant Hospital, Spandau
Collaborators
Humana Inc.
search

1. Study Identification

Unique Protocol Identification Number
NCT02469402
Brief Title
Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality
Official Title
Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein: Content and Improved Protein Quality: LactPro-Minus
Study Type
Interventional

2. Study Status

Record Verification Date
June 2020
Overall Recruitment Status
Completed
Study Start Date
January 2014 (undefined)
Primary Completion Date
December 31, 2016 (Actual)
Study Completion Date
December 31, 2016 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Waldkrankenhaus Protestant Hospital, Spandau
Collaborators
Humana Inc.

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Formula contains significantly higher total protein concentrations than breast milk. Therefore formula-fed infants have a significantly higher total protein intake in the first few months compared to exclusively breast-fed infants. The aim is to examine the nutritive efficacy and safety of a modified infant formula with a reduced protein content and improved protein quality in a prospective, double-blind, controled, randomized study. Primary outcome measures are weight gain and growth of young infants under 12 weeks of dietary intake of the new infant formula. Metabolic effects of the qualitative and quantitative changes in the protein content of the new formula will be recorded. Two groups of healthy bottle-fed infants will be compared. The treatment group will be fed for 3 months with an infant formula with decreased protein content. At the same time the protein body of the new formula is modified by enrichment with bovine alpha-lactalbumin. A control group receives a isocaloric conventional infant formula and a protein body consisting of whey protein and casein in a ratio of 60:40, without specific accumulation of alpha-lactalbumin over the same time-period. A group of breastmilk fed infants will serve as a reference group. In regular anthropometric controls growth and thriving of the study participants is documented and compared between the different groups.
Detailed Description
Breast milk is considered the gold standard for early childhood nutrition, it is optimized in terms of ingredients to the needs of the infant in the first months of life. Formula differ in many ways in their composition to breast milk, e.g. in the structure and concentration of the protein contained. To ensure adequate supply of the infant with all essential and semi-essential amino acids conventional infant formula contains significantly higher total protein concentrations than breast milk. Therefore formula-fed infants have a significantly higher total protein intake in the first few months compared to exclusively breast-fed infants, and individual amino acids are therefore fed in excess. The increased intake of protein, and thus the increased intake of some insulinogenic amino acids in infancy (e.g. the branched chain amino acids leucine, isoleucine and valine), is now considered as a possible co-factor for later disposition to overweight and obesity. Breastfeeding induces slower growth of the infant and is proven to be associated with a lower risk of being overweight or obese at the time of school entry (von Kries 1999). The higher protein intake in bottle-fed babies seems to contribute significantly to the differences that can be observed in the growth behavior between breast-fed and bottle-fed children in the first years of life. Obvious approaches to optimize infant formula are therefore the reduction of protein content, while ensuring an adequate supply of all relevant amino acids similar to breast milk. Enrichment with alpha-lactalbumin enables the reduction of total protein content in the formula through the qualitative upgrading of the protein body and the high content of essential amino acids, thereby limiting a surplus of protein intake, but at the same time to supply adequate amounts of essential amino acids. The aim is to examine the nutritive efficacy and safety of a modified infant formula with a reduced protein content and improved protein quality. Primary outcome measures are weight gain and growth of young infants under the 12 weeks of dietary intake of the new infant formula, and metabolic effects of the qualitative and quantitative changes in the protein content of the new formula. Two groups of healthy bottle-fed infants will be compared. The treatment group will be fed for 3 months with an infant formula with decreased protein content. At the same time the body of experimental protein infant formula was modified by enrichment with bovine alpha-lactalbumin. A control group receives a isocaloric conventional infant formula and a protein body consisting of whey protein and casein in a ratio of 60:40, without specific accumulation of alpha-lactalbumin over the same time period. A group of breastmilk fed infants will serve as a reference group. In regular anthropometric controls growth and thriving of the study participants is documented and compared between the different groups. In addition, laboratory tests are carried out, which will examine the influence of diet on insulin response, protein metabolism and specific growth factors. In a follow-up long-term effects of nutrition on body composition will be recorded by comparing body fat measurements (skinfold thickness-Calipometrie) during the first year of life.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Overweight
Keywords
reduced, protein, formula, Alpha-lactalbumin, infant

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Standard infant formula
Arm Type
Active Comparator
Arm Description
Standard infant formula
Arm Title
Protein reduced formula
Arm Type
Experimental
Arm Description
Protein reduced alpha-lactalbumin formula
Arm Title
Breast-feeding
Arm Type
No Intervention
Arm Description
Exclusive breast-feeding
Intervention Type
Dietary Supplement
Intervention Name(s)
Standard infant formula
Intervention Type
Dietary Supplement
Intervention Name(s)
Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin
Primary Outcome Measure Information:
Title
Composite measure of Growth
Description
height, body weight, head circumference
Time Frame
1 year
Secondary Outcome Measure Information:
Title
Daily fluid intake
Description
ml/kg/d
Time Frame
3 months
Other Pre-specified Outcome Measures:
Title
Plasma concentrations of transthyretin, urea and total protein
Time Frame
3 months
Title
Body Fat Percentage
Description
skinfold thickness-Calipometrie
Time Frame
1 year

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Day
Maximum Age & Unit of Time
1 Month
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: At the time of study enrollment apparently healthy newborns / infants without pronounced hyper- or hypotrophy (age-appropriate weight percentiles > 3 and < 97 according to Voigt et al.) Maternal decision against breastfeeding (for Formula Groups) Exclusion Criteria: Congenital gastrointestinal malformations, metabolic disease, chromosomal aberration, syndromic disease with significant impact on growth, development, nutrition, immune competence Manifestation of a serious disease, which is expected to be accompanied by growth retardation, intestinal transit disruption or the need for special dietary treatment (e.g. hypertrophic pyloric stenosis, cystic fibrosis, Hirschsprung's disease, cow's milk protein intolerance.) Decision to administer HA (hypoallergenic) formula due to family atopies (defined by atopic disease of at least one 1 st degree relative: bronchial asthma, atopic dermatitis, pollinosis) Participation in another nutritional study
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Frank Jochum, Dr. med.
Organizational Affiliation
Paul Gerhard Diakonie
Official's Role
Principal Investigator
Facility Information:
Facility Name
Evangelisches Waldkrankenhaus Spandau
City
Berlin
ZIP/Postal Code
13589
Country
Germany

12. IPD Sharing Statement

Citations:
PubMed Identifier
10406746
Citation
von Kries R, Koletzko B, Sauerwald T, von Mutius E, Barnert D, Grunert V, von Voss H. Breast feeding and obesity: cross sectional study. BMJ. 1999 Jul 17;319(7203):147-50. doi: 10.1136/bmj.319.7203.147.
Results Reference
background

Learn more about this trial

Nutritive Efficacy and Safety of a Modified Infant Formula With a Reduced Protein Content and Improved Protein Quality

We'll reach out to this number within 24 hrs